Can you take Curcumin (turmeric) and Sulforaphane together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

Curcumin (turmeric) vs Sulforaphane

Two of the most-studied food-derived anti-inflammatory / Nrf2-activating compounds.

Reviewed by Read Off Label · How we grade

Score comparison

Sulforaphane has the higher descriptive composite (B+, 7.1/10) compared with Curcumin (turmeric) (C+, 5.5/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Curcumin (turmeric)

C+ 5.5/10

Evidence: Moderate (osteoarthritis pain — multiple MAs show non-inferiority vs NSAIDs and significant WOMAC/VAS reduction; counter-intuitively 2025 network MA found bioavailability-enhanced forms did NOT outperform conventional in OA — WMD -2.47 vs -3.17); Moderate (NAFLD/MASLD — phytosomal curcumin specifically improved ALT/AST and ultrasound findings in RCTs; 2025 MA pooled ALT -5.61 U/L AST -3.90 U/L); Moderate (depression adjunct; metabolic syndrome markers); Weak (cardiovascular outcomes) (6/10)
Benefit: Med (5/10)
Risk: Med (the formulation paradox — hepatotoxicity case reports are concentrated in HIGH-bioavailability formulations: Italian Phytovigilance / Tuscany cluster, DILIN 10-case US series, Icelandic case reports — most linked to Meriva/phytosome or piperine-boosted products at standard supplement doses; rare idiosyncratic non-infectious cholestatic hepatitis; iron chelation potential; theoretical anticoagulant interactions) (5/10 safety)
Legality: OTC (EFSA ADI 180 mg curcumin/day for 60 kg adult ≈ 3 mg/kg/day; Italian Ministry of Health required new hepatotoxicity warning labels 2024-2025)
Dose / route context: 500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin (~20x); phytosome/Meriva (~20-29x AUC); BCM-95 (~7x); Theracurmin (~27x AUC and ~5.6x Cmax vs Meriva); NovaSol micelle (very high Cmax with rapid decline)
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Curcumin (turmeric) as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted.

Studied, labeled, or reported-use context: 500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine… — OTC; not individualized guidance.

What it is

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted. **The formulation paradox is the central biohacker decision input**: bioavailability-enhanced forms (Meriva/phytosome; Theracurmin; BCM-95; NovaSol; piperine-boosted) deliver 5-30x higher plasma curcumin, but hepatotoxicity case reports are CONCENTRATED in exactly these formulations. EFSA, Italian Phytovigilance, DILIN, and Icelandic case clusters all point the same direction — bioavailability-enhanced products at standard supplement doses produce occasional idiosyncratic cholestatic hepatitis. EFSA's 180 mg/day ADI is below typical biohacker dosing. Italian Ministry of Health required new warning labels on Curcuma longa supplements 2024-2025. **OA paradox**: 2025 network MA on knee OA (17 studies) found conventional curcuminoid preparations had numerically LARGER WOMAC pain reduction (-3.17) than bioavailability-enhanced ones (-2.47) — complicates the "phytosomal is better" supplement-industry narrative. NAFLD/MASLD is the strongest specific indication for phytosomal curcumin per the 2025 ALT/AST pooled MA. **Evidence summary for 2024-2025**: conventional curcuminoids showed numerically larger OA estimates than enhanced formulations in the cited network meta-analysis; the EFSA ADI is about 3 mg/kg/day; enhanced-bioavailability formulations are overrepresented in hepatotoxicity reports; and LFT abnormalities, jaundice, dark urine, or right-upper-quadrant pain are clinical hepatotoxicity signals. NAFLD trials include phytosomal formulations under monitoring; the cited OA network meta-analysis produced numerically larger estimates for conventional formulations.

Mechanism

Diferuloylmethane polyphenol from Curcuma longa; pleiotropic effects — NF-κB; COX-2; 5-LOX; JAK-STAT; Nrf2 inhibition/activation across dozens of pathways; native curcumin has <1% oral bioavailability and is rapidly conjugated/excreted; formulation strategies (phytosome, micelle, nanoemulsion, piperine co-administration) raise plasma exposure 5-30x

Full Curcumin (turmeric) review →

Sulforaphane

B+ 7.1/10

Evidence: Moderate (autism — 2025 meta-analysis n=333 across 6 RCTs significant SRS reduction at both 4-5 and 8-10 weeks; Singh 2014 the canonical anchor); Moderate (airborne carcinogen excretion — Kensler 2014 Qidong China demonstrated bladder excretion of acrolein/benzene/crotonaldehyde metabolites); Moderate (schizophrenia negative symptoms and cognition — 2025 RCT positive in chronic schizophrenia); Weak-Moderate (cancer — early-stage prostate and breast signal especially in GSTM1-positive individuals, limited in advanced disease); Moderate (metabolic markers and inflammation across multiple smaller trials) (6/10)
Benefit: Med (5/10)
Risk: Low (well-tolerated; rare GI symptoms; ~50% of completed sulforaphane trials remain unpublished — publication bias caveat from 2025 JNS comprehensive review) (9/10 safety)
Legality: OTC (broccoli sprout extract; preformed sulforaphane products include Avmacol, Prostaphane, BroccoMax)
Dose / route context: 10-40 mg sulforaphane equivalent/day; broccoli sprouts ~30 g/day; or preformed (Avmacol/Prostaphane)
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Sulforaphane as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.

Solid Nrf2-pathway activation with the broadest evidence base of any phytochemical Nrf2 activator.

Studied, labeled, or reported-use context: 10-40 mg sulforaphane equivalent/day; broccoli sprouts ~30 g/day; or preformed (Avmacol/Prostaphane) — OTC; not individualized guidance.

What it is

Solid Nrf2-pathway activation with the broadest evidence base of any phytochemical Nrf2 activator. **Foundational trials**: Singh 2014 (PNAS) autism RCT and Kensler 2014 Qidong air-pollution carcinogen-detox trial remain pivotal anchors. **2024-2025 evidence update**: comprehensive 2025 JNS systematic review (PMID 40988712) catalogued 84 ClinicalTrials.gov-registered sulforaphane trials of which 39 published — flagged a meaningful ~50% publication gap that biohacker writeups systematically miss. 2025 autism meta-analysis (PMC12127520) — n=333 across 6 RCTs confirmed significant Social Responsiveness Scale reduction at both 4-5 and 8-10 weeks. 2025 schizophrenia RCT in chronic patients (J Psychiatr Res) showed significant improvement in negative symptoms and cognition. Cancer evidence remains GSTM1-genotype-stratified — early-stage prostate and breast benefit in GSTM1-positive patients, limited in advanced disease. **Formulation caveat**: native sulforaphane is unstable; cited studies use preformed sulforaphane or glucoraphanin formulations with active myrosinase. Powdered broccoli or glucoraphanin without active myrosinase produces substantially lower sulforaphane exposure because gastric conditions reduce enzyme activity.

Mechanism

Isothiocyanate from broccoli sprouts hydrolyzed from glucoraphanin by myrosinase; activates Nrf2-ARE pathway — upregulates phase II detoxification and antioxidant enzymes (GST/NQO1/HO-1); reversible HDAC inhibitor; autophagy inducer; mitochondrial biogenesis support; native instability requires preformed sulforaphane or co-delivery with active myrosinase

Full Sulforaphane review →

Common questions

How do the evidence profiles of Curcumin (turmeric) and Sulforaphane compare?: Sulforaphane has the higher descriptive composite (B+, 7.1/10) compared with Curcumin (turmeric) (C+, 5.5/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Curcumin (turmeric) and Sulforaphane?: Two of the most-studied food-derived anti-inflammatory / Nrf2-activating compounds.
Can you take Curcumin (turmeric) and Sulforaphane together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.